3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
12
Carcinoma, Hepatocellular
8
Small Cell Lung Carcinoma
7
Cholangiocarcinoma
7
Neoplasms
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms by Site
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Vaccinia
1
Unresectable Hepatocellular Carcinoma
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Cisplatin
6
Paclitaxel
4
pembrolizumab
3
Fluorouracil
3
Carboplatin
3
tislelizumab
2
Taxes
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Injections
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
lenvatinib
1
durvalumab
1
cixutumumab
1
apatinib
1
Tegafur
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiation
1
Levoleucovorin
1
Laparoscopy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Fulvestrant
1
Docetaxel
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
durvalumab
×
30 days
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled